local_hospital

Centre Hospitalier Jean Rougier

Address
lock Available on a paid plan

Musculoskeletal and Immune System Diseases

At Centre Hospitalier Jean Rougier, rheumatology research focuses on rheumatoid arthritis, psoriatic arthritis, and osteoporosis. These studies are exploring new ways to improve symptom control, slow disease activity, and protect bone health in people living with chronic musculoskeletal diseases and immune system diseases.

  • Testing targeted therapies for moderate to severe rheumatoid arthritis
  • Evaluating treatment options for psoriatic arthritis and long-term safety
  • Comparing strategies to maintain bone strength in postmenopausal osteoporosis

These trials aim to improve treatment effectiveness and support better long-term outcomes for patients seen at the site.

Neoplasms and Digestive System Diseases

The site also participates in oncology research across neoplasms and digestive system diseases, including colon carcinoma, anal squamous cell carcinoma, and metastatic oeso-gastric adenocarcinoma. The studies are designed to refine cancer treatment, improve survival, and better match therapy to each patient’s disease profile.

  • Assessing new approaches for colorectal cancer and related high-risk disease
  • Comparing treatment strategies for locally advanced anal cancer
  • Evaluating therapies for metastatic gastroesophageal cancer

Research in this area reflects a strong interest in improving cancer control through more effective and personalized treatment choices.

Breast Cancer and Lymphoma Research

Another important area includes studies in breast cancer and follicular lymphoma. These trials are examining whether newer treatment combinations can improve disease control for patients with ER+ HER2- breast cancer or newly diagnosed lymphoma, while also supporting longer-term outcomes such as progression-free survival and disease-free survival.

  • Comparing treatment approaches for high-risk breast cancer
  • Testing combination strategies in previously untreated follicular lymphoma
  • Studying ways to extend disease-free survival after standard care

These studies help clarify how emerging therapies may improve care for patients with complex or high-risk cancers.

Bacterial Infections and Skin and Connective Tissue Diseases

In the area of bacterial infections and skin and connective tissue diseases, the research includes infections such as catheter-related bloodstream infections and cat scratch disease. The goal is to evaluate more effective infection treatments and improve recovery in patients with difficult-to-manage infectious conditions.

  • Assessing treatment options for Staphylococcus aureus bloodstream infections
  • Exploring a targeted approach for suppurative cat scratch disease
  • Supporting better outcomes in infection-related inflammatory disease

These trials contribute to practical advances in infection care at Centre Hospitalier Jean Rougier and beyond.

Physiological Processes and Acute Kidney Injury

Some studies address broader physiological processes, including recovery after acute kidney injury. This research is looking at ways to improve cardiovascular and overall outcomes after hospital discharge, especially for patients who have partially or fully recovered from a serious kidney event.

  • Evaluating recovery and follow-up care after acute kidney injury
  • Studying strategies to improve cardiovascular outcomes
  • Focusing on recovery after critical care treatment

The aim is to better understand post-hospital recovery and support safer long-term care.

Other Specialized Oncology and Pain Research

The research portfolio also includes studies in less common cancer types and pain conditions, such as neuroendocrine carcinoma, non-small cell lung cancer, and post-surgical neuropathic pain. These trials are testing whether new or adjusted treatment approaches can improve disease control and quality of life.

  • Investigating treatment options for rare and advanced cancers
  • Comparing approaches for lung cancer care
  • Evaluating therapies to reduce post-surgical neuropathic pain

This mix of studies shows a broad clinical research profile with both cancer-focused and symptom-focused investigations.

Site Overview

assignment
21
connected trials
corporate_fare
13
sponsors
science
93
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
2
Trials started 6–12 months ago
21
Total trials linked
Highly Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 9 therapeutic areas and 15 of 93 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 93 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
10
Sponsors (total)
13
Active sponsors
8

Sponsor Network

Top 8 by active trials.

lock +7 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +5 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 978 other sites in France

description
Trial volume
21
Outperforms 81% of sites
public
Therapeutic diversity
9areas
Outperforms 82% of sites
groups
Sponsor diversity
13sponsors
Outperforms 81% of sites

Therapeutic Area Benchmark — France

Select a therapeutic area to compare against other sites in France.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: France

Market Share

Country: France

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Centre Hospitalier Jean Rougier

lock Showing 1 of 21 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A multicentre randomized, double-blind, placebo-controlled, dose-finding, Phase 2 study (MARS-17) of GSK3858279 in adult participants with moderate to severe pain due to knee osteoarthritis.Glaxosmithkline Research & Development LimitedPhase IINot RecruitingNov 2023Aug 2024

IMP list

lock Showing 1 of 93 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Fluorouracil4Unknown2024-02-262026-05-07

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.